JP MORGAN/CALL/BECTON DICKINSON AND CO./260/0.1/17.01.25 Share Price

Warrant

DE000JL1KNU3

Real-time Bid/Ask 11:12:24 07/06/2024 pm IST
1.78 EUR / 1.82 EUR +17.65% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./260/0.1/17.01.25
Current month+29.66%
1 month-12.07%
Date Price Change
07/24/07 1.69 +10.46%
06/24/06 1.53 -9.47%
05/24/05 1.69 +1.81%
04/24/04 1.66 +16.90%
03/24/03 1.42 +20.34%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 12:56 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL1KNU
ISINDE000JL1KNU3
Date issued 05/04/2023
Strike 260 $
Maturity 17/01/2025 (224 Days)
Parity 10 : 1
Emission price 2.88
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 6.17
Lowest since issue 1.01
Spread 0.04
Spread %2.16%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
240.2 USD
Average target price
278.7 USD
Spread / Average Target
+16.04%
Consensus